Table of Contents
TABLE OF CONTENTS
1) INTRODUCTION
1.1 Objective of the Research
1.2 Report Highlights
1.3 Scope of the Report
1.4 Research Methodology
2) MARKET OUTLINE
2.1. Defining the global biosimilar market
2.2. Driving factor analysis
2.2.1. Demand and Supply-side drivers
2.2.2. Restraints & opportunities
2.2.3. Key points
2.3. Issues related with biosimilar
2.4. Potential matrix for global biosimilar
2.4.1. Products
2.4.2. Applications
2.5. Biosimilar market dynamics
2.6. Pricing of biosimilar drug
2.7. Biosimilar products geographical trend
3) BIOSIMILAR PRODUCTS MARKET
3.1. Recombinant glycosylated proteins
3.1.1. Drivers & restraints
3.1.2. Erythropoietin (EPO)
3.1.3. Urokinase
3.1.4. Glucocerebrosidase
3.1.5. Monoclonal antibodies
3.1.5.1. Chimaeric antibodies
3.1.5.2. Humanized / cdr-grafted / reshaped antibodies
3.1.5.3. Human antibodies and fusion protein
3.1.6. Follitropin
3.1.7. Thyrotropin
3.1.8. Becaplermin
3.1.9. Granulocyte-macrophage-CSF (GM-CSF)
3.1.10. Recombinant Human DNASE (RHDNASE)
3.1.11. Factor VIIA
3.1.11.1. Factor VIII
3.1.11.2. Factor IX
3.1.12. Activated protein-c
3.1.13. Tissue plasminogen activator
3.2. Recombinant non-glycosylated protein
3.2.1. Drivers and restraints
3.2.2. Insulin
3.2.2.1. Drivers & restraints
3.2.2.2. Opportunities
3.2.3. Interferons
3.2.3.1. Interferon alfa
3.2.3.2. Interferon beta-1a
3.2.3.3. Interferon gamma
3.2.4. Recombinant human growth hormone
3.2.5. Lepirudin
3.2.6. Interleukin-11
3.2.7. Anakinra
3.2.8. Interleukin – 2 (Il-2)
3.2.9. Granulocyte colony-stimulating factor (G-CSF)
3.3. Peptides
3.3.1. Drivers
3.3.2. Restraints & opportunities
3.3.3. Cyclosporine
3.3.4. Calcitonin
3.3.5. Bivalirudin
3.3.6. Enfuvirtide
3.3.7. Glucagon
3.3.8. Eptifibatide
3.3.9. Octreotide
3.3.10. Desmopressin
3.3.11. LH-RH (Leuprolide)
3.3.12. Nesiritide
3.3.13. Teriparatide
4) BIOSIMILAR TECHNOLOGY
4.1. Recombinant DNA technology (RDNA technology)
4.1.1. Drivers
4.1.2. Restraints & opportunities
4.2. Chromatography
4.2.1. Drivers & opportunities
4.2.2. Top player analysis
4.2.3. Liquid chromatography (LC)
4.2.4. Gas chromatography (GC)
4.3. Bioassay
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Techniques in bioassay
4.3.3.1. Six point assay
4.3.3.2. Multiple point assays
4.3.3.3. Interpolation method
4.3.3.4. Bracketing method
4.3.3.5. Matching bioassays
4.4. Monoclonal antibodies (MAB) technology
4.4.1. Drivers
4.4.2. Restraints & opportunities
4.4.3. Top player analysis
4.5. Western blotting
4.5.1. Drivers
4.5.2. Restraints & opportunities
4.6. Protein sequencing
4.6.1. Drivers
4.6.2. Restraints & opportunities
4.7. Nuclear magnetic resonance (NMR) technology
4.7.1. Drivers
4.7.2. Restraints & opportunities
4.8. Electrophoresis
4.8.1. Drivers
4.8.2. Restraints & opportunities
4.8.3. GEL electrophoresis
4.8.4. Capillary electrophoresis
4.9. Mass spectrometry
4.9.1. Drivers
4.9.2. Restraints
5) BIOSIMILAR APPLICATION MARKET
5.1. Introduction
5.1.1. Drivers
5.1.2. Restraints
5.2. Oncology
5.2.1. Drivers
5.2.2. Restraints & opportunities
5.2.3. Lung cancer
5.2.4. Colorectal cancer
5.2.5. Breast cancer
5.2.6. Cervical cancer
5.2.7. Leukemia
5.2.7.1. Drivers
5.2.8. Prostate cancer
5.3. Infectious diseases
5.3.1. HIV/Aids
5.3.1.1. Drivers
5.3.2. Hepatitis B
5.3.3. Hepatitis C
5.4. Chronic and autoimmune diseases
5.4.1. Diabetes
5.4.1.1. Drivers
5.4.2. Neutropenia
5.4.3. Multiple sclerosis
5.4.3.1. Drivers
5.4.3.2. Inhibitors and opportunities
5.4.4. Cystic fibrosis
5.4.5. Rheumatoid arthritis (RA)
5.4.5.1. Drivers
5.4.5.2. Restraints
5.4.6. Acromegaly
5.4.6.1. Driver
5.4.7. Leprosy
5.5. Hematology
5.5.1. Drivers
5.5.2. Chemotherapy induced anemia
5.5.2.1. Drivers
5.5.2.2. Restraints and opportunities
5.5.3. Hemophilia
5.5.4. Pulmonary embolism
5.5.4.1. Drivers
5.6. Growth hormone deficiency (GHD)
5.6.1. Drivers
5.7. Other diseases
5.7.1. Gaucher disease
5.7.2. Osteoporosis
5.7.3. Fertility disorders (Infertility)
5.7.4. Skin ulcer
5.7.5. Hypoglycemia
5.7.6. Nocturnal enuresis
5.7.7. Congestive heart failure (CHF)
5.7.8. Systemic sepsis
5.7.9. Others
6) BIOSIMILAR SERVICE MARKET
6.1. Clinical trials
6.1.1. Drivers & restraints
6.1.2. Phase I
6.1.3. Phase II
6.1.4. Phase III
6.2. Contract research and manufacturing services
6.2.1. Drivers
6.2.2. Restraints & opportunities
7) GEOGRAPHIC ANALYSIS
7.1. North America biosimilar market
7.2. EMEA biosimilar market
7.3. Asia-Pacific biosimilar market
7.4. Latin America Biosimilars market
8) COMPANY PROFILES
8.1.1. Teva
8.1.2. Sandoz
8.1.3. Hospira
8.1.4. Mylan
8.1.5. Actavis
8.1.6. Biocon Ltd.
8.1.7. Cipla Ltd.
8.1.8. Dr. Reddy's Laboratories Ltd.
8.1.9. Wockhardt Ltd
8.1.10. Stada Arzneimittel AG
